Protocol Title: Efficacy and safety of once-weekly subcutaneous NNC0662-0419 in participants with type 2 diabetes – a dose-finding study

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523260-20-00

Enrollment

Registered

2026-04-21

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Brief summary

Change in HbA1c

Detailed description

Relative change in body weight, Change in body weight

Interventions

DRUGPlacebo A

DRUGSemaglutide B Placebo

DRUGOzempic 0.5 mg solution for injection in pre-filled pen

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Change in HbA1c	—

Secondary

Measure	Time frame
Relative change in body weight, Change in body weight	—

Outcome results

None listed

Source: EU CTIS · Data processed: Apr 23, 2026